January 08, 2025--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare ...

“After a great year of execution across the portfolio, we enter 2025 poised to deliver on a number of important catalysts,” said Steve Mahoney, Viridian’s President and CEO. “We believe ...

Across the recent three months, 10 analysts have shared their insights on Viridian Therapeutics VRDN, expressing a variety of opinions spanning from bullish to bearish. In the table below ...

Viridian Therapeutics, Inc. has a fifty-two week low of $11.40 and a fifty-two week high of $27.20. The firm has a market cap of $1.53 billion, a P/E ratio of -4.48 and a beta of 1.04. The company ...

Viridian Therapeutics is based in Waltham, MA. The company is focused on developing treatments for serious and rare diseases. The company's two most advanced candidates in the clinic (VRDN-001 and ...

The projected fair value for Viridian Therapeutics is US$14.53 based on 2 Stage Free Cash Flow to Equity Viridian Therapeutics' US$19.31 share price signals that it might be 33% overvalued The US$ ...

10 analysts have expressed a variety of opinions on Viridian Therapeutics (NASDAQ:VRDN) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table ...

Viridian Therapeutics (NASDAQ:VRDN) appears to be ending on a high note in 2024, because it just reported positive results from its phase 3 THRIVE-2 study using its anti-IGF-1R drug veligrotug ...

We're building Viridian for living. When you move to Viridian, we want you to have the option to stay here for life." The first phase of homes will be for sale in December 2024. Viridian's ...

As 2024 comes to a close, Leader-Post photojournalist Kayle Neis reflects on five photos that had a big impact on him this year. This exercise is not meant to showcase the “best” photos but ...

"It puts you in a very, very dark place." Gearing will race with the Making Waves Foundation team, crewing the custom-built ocean racing boat Kayle, despite almost walking away from the challenge.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...